Detalhe da pesquisa
1.
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Lancet
; 397(10268): 51-60, 2021 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33338437
2.
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
N Engl J Med
; 381(2): 142-149, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31291516
3.
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Lancet
; 394(10200): 737-745, 2019 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31311674
4.
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
Depress Anxiety
; 27(5): 417-25, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20455246
5.
A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
Schizophr Res
; 84(1): 77-89, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16483745
6.
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
J Clin Psychiatry
; 64(9): 1048-56, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-14628980
7.
Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder.
Psychiatry (Edgmont)
; 6(1): 26-31, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19724740